— PUBLICATIONS —

Liste des publications GINECO - Cancer Ovaire 2014

  • REV Article (Annals of Oncology)
    F. Selle
    A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.
    Annals of Oncology - Novembre 2014 (réf. PubMed : PMID: 25210017 [PubMed - indexed for MEDLINE])
  • AGO-OVAR16/VEG110655 – Article - Original Report (Journal of Clinical Oncology)
    A. du Bois
    Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer.
    Journal of Clinical Oncology - Septembre 2014 (réf. PubMed : PMID : 25225436 [PubMed - as supplied by publisher])
  • AGO-OVAR16/VEG110655 – Article - Editorial (Journal of Clinical Oncology)
    K.E. Oliver
    Ovarian Cancer and Antiangiogenic Therapy: Caveat Emptor.
    Journal of Clinical Oncology - Septembre 2014 (réf. PubMed : PMID : 25225422 [PubMed - as supplied by publisher])
  • Ovarian cancer – Article (The Lancet Oncology)
    G.C. Jayson
    Epithelial ovarian cancer is the commonest cause of gynaecological cancer-associated death. The disease typically presents in postmenopausal women, with a few months of abdominal pain and distension. Most women have advanced disease (International Federation of Gynecology and Obstetrics [FIGO] stage III), for which the standard of care remains surgery and platinum-based cytotoxic chemotherapy. Although this treatment can be curative for most patients with early stage disease, most women with advanced disease will develop many episodes of recurrent disease with progressively shorter disease-free intervals. These episodes culminate in chemoresistance and ultimately bowel obstruction, the most frequent cause of death. For women whose disease continues to respond to platinum-based drugs, the disease can often be controlled for 5 years or more. Targeted treatments such as antiangiogenic drugs or poly (ADP-ribose) polymerase inhibitors offer potential for improved survival. The efficacy of screening, designed to detect the disease at an earlier and curable stage remains unproven, with key results expected in 2015.
    The Lancet Oncology - Octobre 2014 (réf. PubMed : PMID : 24767708 [PubMed - in process])
  • OCTAVIA – Article (European Journal of Cancer)
    A. Gonzalez-Martin
    Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer).
    European Journal of Cancer - Mar 2014 (réf. PubMed : PMID: 24418723 [PubMed - indexed for MEDLINE])
  • Calypso – Article (Gynecologic Oncology)
    M. Wilbaux
    Dynamic modeling in ovarian cancer: An original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development.
    Gynecologic Oncology - Avril 2014 (réf. PubMed : PMID: 24726614 [PubMed - as supplied by publisher])
  • Calypso – Article (British Journal of Cancer)
    M. Wilbaux
    Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients.
    British Journal of Cancer - Mars 2014 (réf. PubMed : PMID: 24556626 [PubMed - in process] - PMCID: PMC3960627 [Available on 2015/3/18])
  • Aurelia – Article (Journal of Clinical Oncology)
    E. Pujade-Lauraine
    Original Reports Rapid Communications: Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial.
    Journal of Clinical Oncology - Mars 2014 (réf. PubMed : PMID: 24637997 [PubMed - in process])
  • Aurelia – Article (Journal of Clinical Oncology)
    E. Pujade-Lauraine
    Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
    Journal of Clinical Oncology - Mai 2014 (réf. PubMed : PMID: 24637997 [PubMed - indexed for MEDLINE])
  • Aurelia – Article (Journal of Clinical Oncology)
    M.R. Stockler
    Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer.
    Journal of Clinical Oncology - Mars 2014 (réf. PubMed : PMID: 24687829 [PubMed - in process])
  • MITO7 – Article (The Lancet Oncology)
    S. Pignata
    Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
    The Lancet Oncology - Février 2014 (réf. PubMed : PMID: 24582486 [PubMed - as supplied by publisher])
  • TARCEVA – Article (Journal of Clinical Oncology)
    I.B. Vergote
    Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.
    Journal of Clinical Oncology - Février 2014 (réf. PubMed : PMID: 24366937 [PubMed - indexed for MEDLINE])
  • TMRO - FOXL2 for sex cord-stromal – Article (Gynecologic Oncology)
    D. Maillet
    Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO network.
    Gynecologic Oncology - Janvier 2014 (réf. PubMed : PMID: 24157616 [PubMed - indexed for MEDLINE])
Haut de page

Modifié le 30-06-2017 15:06